Why This Study Matters
Cervical cancer carries a steep survival drop once disease spreads beyond the pelvis: overall five-year relative survival across all stages is 68.8%, but falls to 20.5% for distant, metastatic-stage disease. The National Cancer Institute projects roughly 13,490 new U.S. cervical cancer diagnoses and 4,200 deaths in 2026, underscoring why durable first-line systemic therapy in persistent, recurrent, or metastatic disease remains a priority.
Pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, was the first anti-PD-1/PD-L1-based regimen to show a significant survival benefit in this setting, and it received FDA approval in October 2021 for tumors with a PD-L1 combined positive score (CPS) of 1 or higher. This ad hoc exploratory analysis asks whether that benefit has held up over a longer stretch of follow-up.
Study Design
KEYNOTE-826 is a phase 3, double-blind, randomized, placebo-controlled trial conducted at 151 sites across 19 countries. Patients with previously untreated persistent, recurrent, or metastatic cervical cancer were randomized to pembrolizumab 200 mg intravenously every 3 weeks (for up to 35 cycles) plus platinum-based chemotherapy with or without bevacizumab, or to placebo plus the same chemotherapy backbone. Enrollment ran from November 20, 2018, to January 31, 2020. This exploratory analysis reflects a median follow-up of 59.1 months (range, 52.1–66.5), compared with 39.1 months at the trial's prior final analysis.
Patient Population
Among the 617 randomized patients, median age was 51.0 years (range, 22–82). At diagnosis, 303 patients (49.1%) had stage I/II disease and 190 (30.8%) had stage IVB disease; 446 patients (72.3%) had squamous cell carcinoma histology.
Efficacy Results
Both overall survival and progression-free survival continued to favor the pembrolizumab combination at this extended follow-up, in both the PD-L1 CPS≥1 population and the overall intention-to-treat population.
| Endpoint | Population | Pembrolizumab Arm | Placebo Arm | Hazard Ratio (95% CI) |
|---|---|---|---|---|
| Overall survival | PD-L1 CPS≥1 | 28.6 mo | 16.5 mo | 0.62 (0.50–0.76) |
| Overall survival | Intention-to-treat | 26.4 mo | 16.8 mo | 0.64 (0.53–0.78) |
| Progression-free survival | PD-L1 CPS≥1 | 10.5 mo | 8.2 mo | 0.58 (0.48–0.71) |
| Progression-free survival | Intention-to-treat | 10.4 mo | 8.2 mo | 0.61 (0.51–0.74) |
The published abstract for this exploratory analysis does not report p-values for these 5-year hazard ratios, and none are stated here to avoid fabricating a statistic the source does not provide. For context only, and not from this analysis: the original 2021 interim data underlying FDA approval reported, in the PD-L1 CPS≥1 population (n=548), median overall survival not reached versus 16.3 months (hazard ratio 0.64) and median progression-free survival 10.4 versus 8.2 months (hazard ratio 0.62).
Subgroup Analyses
The published abstract reports results only for the two pre-specified efficacy populations shown above — it does not break results down further by histology, geographic region, age, or bevacizumab use. Because the full-text manuscript was not accessible for this article (the PMC record for this paper is publisher-embargoed), no additional subgroup-level hazard ratios, confidence intervals, or effect estimates are reported here; that breakdown was simply not available from this source.
Safety Profile
No new safety signals were observed at this roughly five-year follow-up, and no additional treatment-related deaths had occurred since the trial's prior final analysis.
| Adverse Event Category | Pembrolizumab Arm | Placebo Arm |
|---|---|---|
| Treatment-related adverse events (any grade) | Not specified in this source | Not specified in this source |
| Grade ≥3 treatment-related adverse events | Not specified in this source | Not specified in this source |
| Treatment-related deaths since prior final analysis | None additional reported | None additional reported |
Per-arm adverse-event rates were not included in the published abstract for this exploratory analysis, and the full-text manuscript could not be retrieved for this article, so exact percentages are not reported here rather than estimated.
Interpretation and Broader Context
The 5-year data confirm the durability of benefit and reinforce pembrolizumab plus chemotherapy, with or without bevacizumab, as a first-line standard-of-care option for recurrent and metastatic cervical cancer.
— Conclusions and Relevance, Hasegawa et al., JAMA Oncology, September 10, 2026
Taken together with the trial's original 2021 primary-endpoint results and its 2023 final analysis, this exploratory look at roughly five years of follow-up suggests the survival advantage seen early in KEYNOTE-826 has persisted as the cohort has matured, rather than fading as early responders were counted more than once. The authors themselves note that long-term follow-up is important to further inform the benefit-risk profile of anticancer treatments — a reminder that this durability data, while reassuring, is an exploratory analysis layered on top of the trial's original pre-specified endpoints, not a new confirmatory readout.
Limitations
This is an ad hoc exploratory analysis, not a pre-specified confirmatory one: the published abstract reports no p-values for the 5-year overall survival or progression-free survival hazard ratios, so the size of any statistical effect beyond the point estimates and confidence intervals cannot be judged here. Because the underlying full-text manuscript was not accessible for this article — the PMC record carries a publisher embargo — this piece was written from the structured abstract alone, and several things the source did not report are absent rather than estimated: subgroup-level results by histology, region, age, or bevacizumab use, and per-arm adverse-event rates beyond the summary statement that no new safety signals emerged. Readers should treat the survival figures above as descriptive evidence of durability, not as a newly confirmed treatment effect.
In an ad hoc exploratory analysis of KEYNOTE-826 at roughly five years of follow-up (median 59.1 months), adding pembrolizumab to platinum-based chemotherapy, with or without bevacizumab, continued to show longer overall survival (28.6 vs 16.5 months in the PD-L1 CPS≥1 population; hazard ratio 0.62) and progression-free survival than chemotherapy alone in persistent, recurrent, or metastatic cervical cancer, with no new safety signals. The abstract this article was built from reports no p-values for these hazard ratios and no subgroup or detailed safety breakdown, because the full-text manuscript was not accessible this run — so the results here should be read as a durability signal from an exploratory analysis, not a confirmed, newly tested treatment benefit.